FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors


Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22015017560406/25/15 new patent  Tricyclic heterocycles as bet protein inhibitors
32015016490006/18/15Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
42015014834205/28/15Bicyclic heterocycles as bet protein inhibitors
52015014834805/28/15Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
62015014837205/28/15Bicyclic heterocycles as bet protein inhibitors
72015014837505/28/15Bicyclic heterocycles as bet protein inhibitors
82015013367405/14/15Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
92015008763203/26/15Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
102015008766203/26/15Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
112015006544703/05/15Survival benefit in patients with solid tumors with elevated c-reactive protein levels
122015006548403/05/15Sustained release dosage forms for a jak1 inhibitor
132015005726502/26/15Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
142015002505601/22/15Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
152015001717301/15/15Antibodies to human transmembrane proteins
162015001154001/08/15Tricyclic heterocycles as bet protein inhibitors
172015000416501/01/15Secreted proteins
182014037729212/25/14Modulators of indoleamine 2,3-dioxygenase and methods of using the same
192014037840012/25/14Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
202014037121612/18/14Purinone derivatives as hm74a agonists
212014034303011/20/14Bipyrazole derivatives as jak inhibitors
222014031596210/23/141,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
232014027503009/18/14Tricyclic heterocycles as bet protein inhibitors
242014027503109/18/14Piperidin-4-yl azetidine derivatives as jak1 inhibitors
252014027512709/18/14Substituted heteroaryl fused derivatives as pi3k inhibitors
262014025694109/11/14Processes and intermediates for making a jak inhibitor
272014024913209/04/14Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
282014024208608/28/14Polynucleotides encoding signal peptide-containing molecules
292014024330808/28/14Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
302014024336008/28/14Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
312014022727508/14/14Methods of treating and diagnosing pancreatitis
322014022727808/14/14Antibodies to human signal peptide-containing proteins
332014022834608/14/14Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
342014022137908/07/14N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
352014020021607/17/14Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
362014020022707/17/14Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
372014018753007/03/14Aza spiro alkane derivatives as inhibitors of metalloproteases
382014017140506/19/14Fused pyrazoles as fgfr inhibitors
392014017140906/19/14Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
402014015528806/05/14Methods for diagnosing cancer
412014015537706/05/143-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
422014015540406/05/14Piperazinylpiperidine derivatives as chemokine receptor antagonists
432014013535005/15/14Sustained-release dosage forms of ruxolitinib
442014012119805/01/14Tricyclic fused thiophene derivatives as jak inhibitors
452014012122205/01/14Pyrimidinones as pi3k inhibitors
462014006644803/06/14Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
472014005690602/27/14Secreted proteins
482014005791202/27/14Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
492014004581402/13/14Pyrazine derivatives as fgfr inhibitors
502014003134401/30/14Azepine inhibitors of janus kinases
512014002366301/23/141,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
522014001837401/16/14Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
532014000516601/02/14Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
542014000521001/02/14Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
552013034515712/26/13Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
562013034522412/26/13Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
572013032451512/05/13Imidazotriazines and imidazopyrimidines as kinase inhibitors
582013025319009/26/13Processes for preparing jak inhibitors and related intermediate compounds
592013025319109/26/13Processes for preparing jak inhibitors and related intermediate compounds
602013025319309/26/13Processes for preparing jak inhibitors and related intermediate compounds
612013024378109/19/13Signal peptide-containing proteins
622013024492709/19/13Polynucleotides encoding signal peptide-containing molecules
632013024499909/19/13Substituted heterocyclic compounds
642013022476908/29/13Methods of using chemokine panec-1 antibodies
652013022555608/29/13Azetidine and cyclobutane derivatives as jak inhibitors
662013019025007/25/13Polynucleotides encoding human signal peptide-containing proteins
672013017759007/11/13N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
682013013768105/30/13Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
692013012324605/16/13Modulators of indoleamine 2,3-dioxygenase and methods of using the same
702013011623005/09/133-aminopyrrolidine derivatives as modulators of chemokine receptors
712013009614404/18/13Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
722013005894203/07/13Human beta-adrenergic receptor kinase polypeptide and methods
732013005983503/07/13Heterocyclylamines as pi3k inhibitors
742013006002603/07/13Processes and intermediates for making a jak inhibitor
752013004596302/21/13Cyclohexyl azetidine derivatives as jak inhibitors
762013001803401/17/13Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
772013001806801/17/13Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
782012032978212/27/12Azepine inhibitors of janus kinases
792012030146411/29/12Janus kinase inhibitors for treatment of dry eye and other eye related diseases
802012029591211/22/12Piperazinylpiperidine derivatives as chemokine receptor antagonists
812012027080910/25/12Human transmembrane proteins
822012012285805/17/12Lactam compounds and their use as pharmaceuticals
832012004096402/16/12N-substituted piperidines and their use as pharmaceuticals
842012003517202/09/12Purinone derivatives as hm74a agonists
852012001493701/19/12Human beta-adrenergic receptor kinase polypeptide and methods
862012001592801/19/12Amido compounds and their use as pharmaceuticals
872011025121510/13/11Macrocyclic compounds and their use as kinase inhibitors
882011021296709/01/11Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
892011020775408/25/11Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
902011013678106/09/11Imidazotriazines and imidazopyrimidines as kinase inhibitors
912011008681004/14/11Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
922011008215904/07/11Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
932011005321703/03/11Polynucleotides encoding signal peptide-containing molecules
942010027933311/04/10Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
952010025611410/07/10Amido compounds and their use as pharmaceuticals
962010024067109/23/10Substituted heterocyclic compounds
972010020303908/12/103-aminocyclopentanecarboxamides as modulators of chemokine receptors
982010019080407/29/10Macrocyclic compounds and their use as kinase inhibitors
992010017390107/08/10Substituted heterocyclic compounds
1002010013740106/03/102-methylprop anamides and their use as pharmaceuticals
1012010011950305/13/103-aminocyclopentanecarboxamides as modulators of chemokine receptors
1022010009961704/22/10Secreted proteins
1032009031840512/24/094-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1042009029194611/26/09Lactam compounds and their use as pharmaceuticals
1052009028677411/19/09Purinone derivatives as hm74a agonists
1062009028677811/19/09Macrocyclic compounds and their use as kinase inhibitors
1072009027468011/05/09Human phospholipases
1082009023390309/17/09Azetidine and cyclobutane derivatives as jak inhibitors
1092009021576608/27/09Tetracyclic inhibitors of janus kinases
1102009019788708/06/09Piperazinylpiperidine derivatives as chemokine receptor antagonists
1112009018195907/16/09Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1122009012464905/14/09Aza spiro alkane derivatives as inhibitors of metalloproteases
1132009008844604/02/09Purinone derivatives as hm74a agonists
1142009007626903/19/09Purinone derivatives as hm74a agonists
1152012026367610/18/12Compositions, methods and kits relating to her-2 cleavage
1162012005807903/08/121,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1172012001498901/19/12Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1182011031147912/22/11Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1192011022321009/15/11Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1202011022415709/15/11Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1212011017227907/14/11N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1222011016518807/07/11N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1232011008683504/14/11Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1242009029880812/03/09Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1252009019786908/06/09Azepine inhibitors of janus kinases



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE